DALS — DA32 Life Science Tech Acquisition Balance Sheet
0.000.00%
Last trade - 00:00- $264.71m
- $264.40m
- 46
- 41
- 44
- 39
Annual balance sheet for DA32 Life Science Tech Acquisition, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | |
|---|---|---|
| Period Length: | — | — |
| Source: | 10-K | 10-K |
| Standards: | USG | USG |
| Status: | Final | Final |
| Cash | ||
| Cash and Short Term Investments | 1.86 | 0.699 |
| Prepaid Expenses | ||
| Total Current Assets | 2.47 | 0.929 |
| Long Term Investments | ||
| Total Assets | 202 | 204 |
| Accounts Payable | ||
| Accrued Expenses | ||
| Notes Payable / Short Term Debt | ||
| Total Other Current Liabilities | ||
| Total Current Liabilities | 0.287 | 1.05 |
| Total Long Term Debt | ||
| Total Debt | ||
| Deferred Income Tax | ||
| Total Liabilities | 5.89 | 6.65 |
| Common Stock | ||
| Additional Paid In Capital | ||
| Retained Earnings (Accumulated Deficit) | ||
| Total Equity | 197 | 197 |
| Total Liabilities & Shareholders' Equity | 202 | 204 |
| Total Common Shares Outstanding |